Skip to content
2000
Volume 14, Issue 2
  • ISSN: 1570-1638
  • E-ISSN: 1875-6220

Abstract

Drug development has moved along way forward from the days of with doctors peddling cauldrons of herbs and spices, however, the process can still miss opportunities for full exploitation of a drug’s potential. Drug reprofiling provides a chance for an established or a forgotten drug to move into a new area of therapy, whether related to the known effects or in a completely new area. In an era of environmental awareness and spiraling costs for traditional drug development, a strategy to squeeze every benefit out of drugs with known safety, tolerability and pharmacological parameters must be a strategically sound desire. We explore examples of success in reprofiling, draw comparisons between techniques, and finally provide two examples from the Valirx plc development pipeline currently undergoing the process.

Loading

Article metrics loading...

/content/journals/cddt/10.2174/1570163814666170117120005
2017-06-01
2025-01-09
Loading full text...

Full text loading...

/content/journals/cddt/10.2174/1570163814666170117120005
Loading

  • Article Type:
    Research Article
Keyword(s): cancer; development; health economics; Reprofiling; risperidone; techniques
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test